JP2025511183A5 - - Google Patents
Info
- Publication number
- JP2025511183A5 JP2025511183A5 JP2024558017A JP2024558017A JP2025511183A5 JP 2025511183 A5 JP2025511183 A5 JP 2025511183A5 JP 2024558017 A JP2024558017 A JP 2024558017A JP 2024558017 A JP2024558017 A JP 2024558017A JP 2025511183 A5 JP2025511183 A5 JP 2025511183A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- item
- compound according
- modified
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263326733P | 2022-04-01 | 2022-04-01 | |
| US63/326,733 | 2022-04-01 | ||
| US202263407071P | 2022-09-15 | 2022-09-15 | |
| US63/407,071 | 2022-09-15 | ||
| PCT/US2023/017185 WO2023192630A2 (en) | 2022-04-01 | 2023-03-31 | Angiotensinogen-modulating compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511183A JP2025511183A (ja) | 2025-04-15 |
| JP2025511183A5 true JP2025511183A5 (https=) | 2026-04-08 |
Family
ID=88203363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024558017A Pending JP2025511183A (ja) | 2022-04-01 | 2023-03-31 | アンジオテンシノーゲンを調節する組成物及びその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240041913A1 (https=) |
| EP (1) | EP4504937A2 (https=) |
| JP (1) | JP2025511183A (https=) |
| KR (1) | KR20240168424A (https=) |
| CN (1) | CN119137272A (https=) |
| AU (1) | AU2023245480A1 (https=) |
| CA (1) | CA3255793A1 (https=) |
| CL (1) | CL2024002910A1 (https=) |
| CO (1) | CO2024013353A2 (https=) |
| IL (1) | IL315862A (https=) |
| MX (1) | MX2024012080A (https=) |
| PE (1) | PE20242356A1 (https=) |
| TW (1) | TW202405171A (https=) |
| WO (1) | WO2023192630A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240401045A1 (en) * | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| IL312811A (en) * | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287570A1 (en) * | 2004-05-26 | 2005-12-29 | Wyeth | Probe arrays for expression profiling of rat genes |
| WO2011156734A2 (en) * | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
| WO2014018930A1 (en) * | 2012-07-27 | 2014-01-30 | Isis Pharmaceuticals. Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
-
2023
- 2023-03-31 US US18/194,203 patent/US20240041913A1/en active Pending
- 2023-03-31 KR KR1020247036043A patent/KR20240168424A/ko active Pending
- 2023-03-31 TW TW112112620A patent/TW202405171A/zh unknown
- 2023-03-31 EP EP23781897.6A patent/EP4504937A2/en active Pending
- 2023-03-31 WO PCT/US2023/017185 patent/WO2023192630A2/en not_active Ceased
- 2023-03-31 CA CA3255793A patent/CA3255793A1/en active Pending
- 2023-03-31 PE PE2024002116A patent/PE20242356A1/es unknown
- 2023-03-31 IL IL315862A patent/IL315862A/en unknown
- 2023-03-31 JP JP2024558017A patent/JP2025511183A/ja active Pending
- 2023-03-31 CN CN202380037505.2A patent/CN119137272A/zh active Pending
- 2023-03-31 AU AU2023245480A patent/AU2023245480A1/en active Pending
-
2024
- 2024-09-27 CL CL2024002910A patent/CL2024002910A1/es unknown
- 2024-09-30 CO CONC2024/0013353A patent/CO2024013353A2/es unknown
- 2024-09-30 MX MX2024012080A patent/MX2024012080A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024536146A5 (https=) | ||
| JP2024541771A5 (https=) | ||
| JP2025511183A5 (https=) | ||
| JP2021074021A5 (https=) | ||
| JP2018199700A5 (https=) | ||
| JP2021074010A5 (https=) | ||
| JP2023536974A5 (https=) | ||
| JP2022519019A5 (https=) | ||
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2018150344A5 (https=) | ||
| EA022429B1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| JPH08508491A (ja) | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド | |
| JPH11511436A (ja) | 化学化合物、それらの調製及び使用 | |
| JP2012505660A5 (https=) | ||
| JP2020511155A5 (https=) | ||
| JP2021090458A5 (https=) | ||
| JP2012529295A (ja) | ｍｉＲＮＡ阻害剤およびミメティクスの化学修飾モチーフ | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| IL277970B1 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugate groups for use in treating end stage renal disease, chronic kidney disease, and coronary artery disease | |
| JP2009539765A (ja) | Ａ２ａｒアゴニストとしての置換されたアリールピペリジニルアルキニルアデノシン | |
| JP2019525918A5 (https=) | ||
| JP2014503192A (ja) | 塩基修飾オリゴヌクレオチド | |
| JP2024543496A5 (https=) | ||
| JP2022520986A5 (https=) |